Ressources - Page 29 sur 42 - Oncodesign Services

Home . 2009 – Humanized mouse model for in vivo antibody-dependent cell-mediated cytotoxicity evaluation

02/06/2015

[FR] Cercle Finance – Oncodesign : UCB exerce son option sur un programme

02/06/2015

[FR] Le Point – Oncodesign : UCB acquiert des droits pour une sélection de molécules

26/05/2015

[FR] Le Revenu – Nos questions à Philippe Genne, PDG d’Oncodesign

Communiqué de Presse

28/04/2015

Oncodesign presents new supportive data for its Nanocyclix based RIPK2 program for auto-immune disease at the 10th Drug Discovery Chemistry conference in San Diego, CA

Communiqué de Presse

26/03/2015

Oncodesign signs additional 2-year preclinical research contract to evaluate antibody-drug conjugates

Poster

01/01/2015

EORTC 2015 – Tumor infiltrating lymphocytes as a biomarker of response for CTLA-4 targeting therapies

Poster

01/01/2015

EORTC 2015 – Efficacy of PD-1 / PD-L1 pathway disruptors in syngeneic models

Poster

01/01/2015

AACR 2015 – Evaluation of immuno-oncology related treatment in syngenic mouse models

Poster

01/01/2015

AACR 2015 – In vivo TK-NOG liver-humanized model to predict patient pharmacological profile of anti-cancer agents

In vivo model in Oncology for drug discovery : TK-NOG liver-humanized model to predict patient pharmacological profile of anti-cancer agents.

Poster

01/01/2015

Identification and characterization of a novel LRRK2 kinase inhibitor: ODS2005294

Communiqué de Presse

17/12/2014

Europe – Oncodesign has entered into a services agreement with Eisai to develop a new personalized medicine program in earlier line metastatic breast cancer treatment

Communiqué de Presse

04/11/2014

Oncodesign announces the third extension of a research contract with Isarna Therapeutics

1 2 … 28 29 30 … 41 42

Contactez-nous

20 rue Jean Mazen - FR - 21000 Dijon
Tél.+33 380 788 260

Je prends contact

La science vient à vous

Recevez nos informations générales !